{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:17:09Z","timestamp":1769883429508,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07589-1","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:13:59Z","timestamp":1758788039000},"page":"1782-1788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5421-7019","authenticated-orcid":false,"given":"Qaid Ahmed","family":"Shagera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Gheysens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Jonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Seront","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Lhommel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic E.","family":"Lecouvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Jamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"7589_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7589_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1634\/theoncologist.2013-0472","volume":"19","author":"CJ Ryan","year":"2014","unstructured":"Ryan CJ, Saylor PJ, Everly JJ, Sartor O. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist. 2014;19:1012\u20138.","journal-title":"Oncologist"},{"key":"7589_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320.","journal-title":"N Engl J Med"},{"key":"7589_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"7589_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738\u201346.","journal-title":"Lancet Oncol"},{"key":"7589_CR6","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/j.eururo.2020.06.022","volume":"78","author":"P Cornford","year":"2020","unstructured":"Cornford P, Grummet J, Fanti S. Prostate-specific membrane antigen positron emission tomography scans before curative treatment: ready for prime time? Eur Urol. 2020;78:e125\u20138.","journal-title":"Eur Urol"},{"key":"7589_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","volume":"45","author":"TD Poeppel","year":"2018","unstructured":"Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7589_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.011","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011.","journal-title":"Ann Oncol"},{"key":"7589_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","volume":"16","author":"MJ Morris","year":"2019","unstructured":"Morris MJ, Corey E, Guise TA, Gulley James L., Kevin Kelly William, Quinn David I., et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16:745\u201356.","journal-title":"Nat Rev Urol"},{"key":"7589_CR10","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","volume":"23","author":"MI Suominen","year":"2017","unstructured":"Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res. 2017;23:4335\u201346.","journal-title":"Clin Cancer Res"},{"key":"7589_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00259-015-3185-4","volume":"43","author":"EC Etchebehere","year":"2016","unstructured":"Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016;43:8\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7589_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00003072-199402000-00009","volume":"19","author":"L Bern\u00e1","year":"1994","unstructured":"Bern\u00e1 L, Torres G, Carri\u00f3 I, Estorch M, Germ\u00e1 JR, Alonso C. Antigranulocyte antibody bone marrow scans in cancer patients with metastatic bone superscan appearance. Clin Nucl Med. 1994;19:121\u20138.","journal-title":"Clin Nucl Med"},{"key":"7589_CR13","first-page":"1485","volume":"35","author":"O Rieker","year":"1994","unstructured":"Rieker O, Gr\u00fcnwald F, Layer G, Kurbacher CM, Hotze AL, Menzel C, et al. Disseminated bone marrow metastases from primary breast cancer: detection and follow-up by radioimmune bone marrow scintigraphy. J Nucl Med. 1994;35:1485\u20137.","journal-title":"J Nucl Med"},{"key":"7589_CR14","first-page":"2295","volume":"32","author":"L Bern\u00e1","year":"1991","unstructured":"Bern\u00e1 L, Germ\u00e1 JR, Estorch M, Torres G, Blanco R, Carri\u00f3 I. Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma. J Nucl Med. 1991;32:2295\u20138.","journal-title":"J Nucl Med"},{"key":"7589_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1531-0","author":"A Agool","year":"2011","unstructured":"Agool A, Glaudemans AWJM, Boersma HH, Dierckx RAJO, Vellenga E, Slart RHJA. Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging. 2011. https:\/\/doi.org\/10.1007\/s00259-010-1531-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7589_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s002560050423","volume":"27","author":"BC Vande Berg","year":"1998","unstructured":"Vande Berg BC, Malghem J, Lecouvet FE, Maldague B. Magnetic resonance imaging of the normal bone marrow. Skeletal Radiol. 1998;27:471\u201383.","journal-title":"Skeletal Radiol"},{"key":"7589_CR17","unstructured":"Piney A. The anatomy of the bone marrow: with special reference to the distribution of the red marrow [Internet]. JSTOR; 1992 [cited 2025 Jun 16]. Available from: http:\/\/www.jstor.org\/stable\/20421458. Accessed 16 June 2025."},{"key":"7589_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1464-410X.1989.tb05943.x","volume":"63","author":"G Haddock","year":"1989","unstructured":"Haddock G, Gray HW, McKillop JH, Bessent RG, Kirk D. 99mTc-nanocolloid bone marrow scintigraphy in prostatic cancer. Br J Urol. 1989;63:497\u2013502.","journal-title":"Br J Urol"},{"key":"7589_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(89)91309-3","volume":"1","author":"SN Reske","year":"1989","unstructured":"Reske SN, Karstens JH, Gloeckner W, Steinstr\u00e4sser A, Schwarz A, Ammon J, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet. 1989;1:299\u2013301.","journal-title":"Lancet"},{"key":"7589_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00006231-199902000-00005","volume":"20","author":"M Laci\u0107","year":"1999","unstructured":"Laci\u0107 M, Bokuli\u0107 T, Lukac J, Kovaci\u0107 K, Baum RP, Kusi\u0107 Z. Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. Nucl Med Commun. 1999;20:135\u201343.","journal-title":"Nucl Med Commun"},{"key":"7589_CR21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s00259-024-06693-y","volume":"51","author":"C Lauri","year":"2024","unstructured":"Lauri C, Noriega-\u00c1lvarez E, Chakravartty RM, Gheysens O, Glaudemans AWJM, Slart RHJA, et al. Diagnostic imaging of the diabetic foot: an EANM evidence-based guidance. Eur J Nucl Med Mol Imaging. 2024;51:2229\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7589_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00259-010-1531-0","volume":"38","author":"A Agool","year":"2011","unstructured":"Agool A, Glaudemans AWJM, Boersma HH, Dierckx RAJO, Vellenga E, Slart RHJA. Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging. 2011;38:166\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7589_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi S, Lin CY, Kelly WK, Fizazi Karim S., Moul Judd W., Kaplan Ellen B., et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671\u20137.","journal-title":"J Clin Oncol"},{"key":"7589_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","volume":"28","author":"O Sartor","year":"2017","unstructured":"Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28:1090\u20137.","journal-title":"Ann Oncol"},{"key":"7589_CR25","doi-asserted-by":"crossref","unstructured":"Zhou B, Raval AD, Zhang Y, Sambamoorthi N, Korn MJ, Constantinovici N et al. Utilization patterns and survival in older men with metastatic prostate cancer treated with Radium-223 in the united states: a SEER-medicare study. Clin Genitourin Cancer. 2025;102372.","DOI":"10.1016\/j.clgc.2025.102372"},{"key":"7589_CR26","doi-asserted-by":"crossref","unstructured":"Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR. Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the united States. Prostate Cancer Prostatic Dis. 2025.","DOI":"10.1038\/s41391-025-00969-6"},{"key":"7589_CR27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/jmri.26759","volume":"50","author":"JP Hynes","year":"2019","unstructured":"Hynes JP, Hughes N, Cunningham P, Kavanagh EC, Eustace SJ. Whole-body MRI of bone marrow: a review. J Magn Reson Imaging. 2019;50:1687\u2013701.","journal-title":"J Magn Reson Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07589-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:21Z","timestamp":1769834601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7589"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07589-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the principles of the Declaration of Helsinki and its later amendments. Approval was granted by the Cliniques universitaires Saint-Luc Ethics Committee (ID: 2025\/23MAI\/202).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for written informed consent was waived due to the retrospective design of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}